Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Cytomegalovirus infection after autologous transplantation in patients with multiple myeloma exposed to daratumumab

Bone Marrow Transplantation volume 60, pages 1181–1183 (2025)Cite this article

Subjects

Access through your institution
Buy or subscribe

TO THE EDITOR:

Cytomegalovirus (CMV) infection is a common complication after autologous hematopoietic stem-cell transplantation (ASCT) in patients with multiple myeloma (MM). Incidence ranges 15–50%, depending on several factors such as patient- and disease characteristics, prior therapies, methods of detection, and monitoring strategies [1,2,3,4]. Conversely, CMV disease post-ASCT is uncommon (1–10%) [3, 5]. Exposure to bortezomib and infusion of CD34+ selected autograft are major risk factors for symptomatic CMV infection [4, 5], while the role of tandem-ASCT is uncertain [2, 6].

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Data availability

Original data are available in anonymous form upon request by contacting corresponding author.

References

  1. Peggs KS, Verfuerth S, Pizzey A, Khan N, Moss P, Goldstone AH, et al. Reconstitution of T-cell repertoire after autologous stem cell transplantation: Influence of CD34 selection and cytomegalovirus infection. Biol Blood Marrow Transpl. 2003;9:198–205.

    Article  CAS  Google Scholar 

  2. Kim JH, Goulston C, Sanders S, Lampas M, Zangari M, Tricot G, et al. Cytomegalovirus reactivation following autologous peripheral blood stem cell transplantation for multiple myeloma in the era of novel chemotherapeutics and tandem transplantation. Biol Blood Marrow Transpl. 2012;18:1753–8.

    Article  Google Scholar 

  3. Massoud R, Assi R, Fares E, Haffar B, Charafeddine M, Kreidieh N, et al. Cytomegalovirus reactivation in lymphoma and myeloma patients undergoing autologous peripheral blood stem cell transplantation. J Clin Virol. 2017;95:36–41.

    Article  CAS  PubMed  Google Scholar 

  4. Marchesi F, Pimpinelli F, Ensoli F, Mengarelli A. Cytomegalovirus infection in hematologic malignancy settings other than the allogeneic transplant. Hematol Oncol. 2018;36:381–91.

    Article  CAS  PubMed  Google Scholar 

  5. Marchesi F, Mengarelli A, Giannotti F, Tendas A, Anaclerico B, Porrini R, et al. High incidence of post-transplant cytomegalovirus reactivations in myeloma patients undergoing autologous stem cell transplantation after treatment with bortezomib-based regimens: A survey from the Rome Transplant Network. Transpl Infect Dis. 2014;16:158–64.

    Article  CAS  PubMed  Google Scholar 

  6. Marchesi F, Pimpinelli F, Dessanti ML, Gumenyuk S, Palombi F, Pisani F, et al. Evaluation of risk of symptomatic cytomegalovirus reactivation in myeloma patients treated with tandem autologous stem cell transplantation and novel agents: A single-institution study. Transpl Infect Dis. 2014;16:1032–8.

    Article  CAS  PubMed  Google Scholar 

  7. Krejcik J, Casneuf T, Nijhof IS, Verbist B, Bald J, Plesner T, et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016;128:384–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Nahi H, Chrobok M, Gran C, Lund J, Gruber A, Gahrton G, et al. Infectious complications and NK cell depletion following daratumumab treatment of multiple myeloma. PLoS One. 2019;14:e0211927.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Vassilopoulos S, Vassilopoulos A, Kalligeros M, Shehadeh F, Mylonakis E. Cumulative incidence and relative risk of infection in patients with multiple myeloma treated with anti-CD38 monoclonal antibody-based regimens: a systematic review and meta-analysis. Open Forum Infect Dis. 2022;9:ofac574.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Ljungman P, Boeckh M, Hirsch HH, Josephson F, Lundgren J, Nichols G, et al. Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials. Clin Infect Dis. 2017;64:87–91.

    Article  PubMed  Google Scholar 

  11. Girmenia C, Lazzarotto T, Bonifazi F, Patriarca F, Irrera G, Ciceri F, et al. Assessment and prevention of cytomegalovirus infection in allogeneic hematopoietic stem cell transplant and in solid organ transplant: A multidisciplinary consensus conference by the Italian GITMO, SITO, and AMCLI societies. Clin Transplant. 2019;33:e13666.

    Article  PubMed  Google Scholar 

  12. Johnsrud AJ, Johnsrud JJ, Susanibar SA, Kamimoto JJ, Kothari A, Burgess M, et al. Infectious and immunological sequelae of daratumumab in multiple myeloma. Br J Haematol. 2019;185:187–9.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine and Aging Sciences, “G d’Annunzio” University, Chieti, Italy

    Carmine Liberatore, Mario D’Uva, Francesco Guardalupi, Lucia Di Re & Mauro Di Ianni

  2. Hematology Unit, Santo Spirito Hospital, Pescara, Italy

    Carmine Liberatore, Mario D’Uva, Annalisa Natale, Francesca Fioritoni, Stefano Pulini, Raffaele Spadano, Doriana Vaddinelli, Stella Santarone & Mauro Di Ianni

Authors
  1. Carmine Liberatore
    View author publications

    Search author on:PubMed Google Scholar

  2. Mario D’Uva
    View author publications

    Search author on:PubMed Google Scholar

  3. Annalisa Natale
    View author publications

    Search author on:PubMed Google Scholar

  4. Francesco Guardalupi
    View author publications

    Search author on:PubMed Google Scholar

  5. Lucia Di Re
    View author publications

    Search author on:PubMed Google Scholar

  6. Francesca Fioritoni
    View author publications

    Search author on:PubMed Google Scholar

  7. Stefano Pulini
    View author publications

    Search author on:PubMed Google Scholar

  8. Raffaele Spadano
    View author publications

    Search author on:PubMed Google Scholar

  9. Doriana Vaddinelli
    View author publications

    Search author on:PubMed Google Scholar

  10. Stella Santarone
    View author publications

    Search author on:PubMed Google Scholar

  11. Mauro Di Ianni
    View author publications

    Search author on:PubMed Google Scholar

Contributions

All co-authors (CL; MD, AN, FG; LDR; FF, SP, RS, DV; SS, MDI) contributed to patients’ clinical care. CL: writing of the manuscript. FG and LDR: data editing, statistical analysis. MD: data acquisition. All the authors revised and approved the published version of the manuscript.

Corresponding author

Correspondence to Carmine Liberatore.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liberatore, C., D’Uva, M., Natale, A. et al. Cytomegalovirus infection after autologous transplantation in patients with multiple myeloma exposed to daratumumab. Bone Marrow Transplant 60, 1181–1183 (2025). https://doi.org/10.1038/s41409-025-02624-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41409-025-02624-z

Search

Advanced search

Quick links